卡博替尼对比舒尼替尼一线治疗中高危转移性肾细胞癌:独立审查无进展生存与总生存更新
CABOSUN随机2期试验纳入157例IMDC中危或高危晚期肾细胞癌初治患者,1:1随机接受卡博替尼或舒尼替尼。独立影像审查委员会评估的中位无进展生存期为8.6个月对5.3个月(HR 0.48,95%CI 0.31-0.74,P=0.0008),客观缓解率20%对9%;中位随访34.5个月时中位总生存期26.6个月对21.2个月(HR 0.80,95%CI 0.53-1.21)。
要点
- 独立审查确认卡博替尼较舒尼替尼显著延长中高危晚期肾细胞癌初治患者的无进展生存期。
- 卡博替尼组客观缓解率20%,舒尼替尼组9%(独立审查评估)。
- 总生存更新显示HR 0.80(95%CI 0.53-1.21),差异未达统计学显著。
核心结论
- 在中高危晚期肾细胞癌初治患者中,卡博替尼较舒尼替尼显著延长独立审查评估的无进展生存期。
研究设计与样本
- 随机2期CABOSUN试验纳入157例既往未治的IMDC中危或高危晚期肾细胞癌患者,1:1随机分配至卡博替尼60 mg每日一次或舒尼替尼50 mg每日一次(服4周停2周)。
- 按风险组和骨转移 presence 进行分层。
主要发现
- 独立审查中位无进展生存期卡博替尼8.6个月(95%CI 6.8-14.0)对舒尼替尼5.3个月(95%CI 3.0-8.2),HR 0.48(95%CI 0.31-0.74),双侧P=0.0008。
- 独立审查客观缓解率卡博替尼20%(95%CI 12.0-30.8)对舒尼替尼9%(95%CI 3.7-17.6)。
- 中位随访34.5个月,中位总生存期卡博替尼26.6个月(95%CI 14.6-不可估计)对舒尼替尼21.2个月(95%CI 16.3-27.4),HR 0.80(95%CI 0.53-1.21)。
- 3级或4级不良事件发生率卡博替尼68%、舒尼替尼65%。
- 按分层因素和MET肿瘤表达进行的无进展生存亚组分析与总体人群结果一致。
临床怎么用
- 对于IMDC中危或高危的晚期肾细胞癌初治患者,卡博替尼可作为一线治疗选择,其独立审查无进展生存期优于舒尼替尼。
局限性
- 本研究为2期随机试验,样本量157例,总生存期差异未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The randomised phase 2 CABOSUN trial comparing cabozantinib with sunitinib as initial therapy for advanced renal cell carcinoma (RCC) of intermediate or poor risk met the primary end-point of improving progression-free survival (PFS) as assessed by investigator. We report PFS by independent radiology review committee (IRC) assessment, ORR per IRC and updated overall survival (OS). PATIENTS AND METHODS: Previously untreated patients with advanced RCC of intermediate or poor risk by IMDC criteria were randomised 1:1 to cabozantinib 60 mg daily or sunitinib 50 mg daily (4 weeks on/2 weeks off). Stratification was by risk group and presence of bone metastases. RESULTS: A total of 157 patients were randomised 1:1 to cabozantinib (n = 79) or sunitinib (n = 78). Median PFS per IRC was 8.6 months (95% confidence interval [CI] 6.8-14.0) versus 5.3 months (95% CI 3.0-8.2) for cabozantinib versus sunitinib (hazard ratio [HR] 0.48 [95% CI 0.31-0.74]; two-sided p = 0.0008), and ORR per IRC was 20% (95% CI 12.0-30.8) versus 9% (95% CI 3.7-17.6), respectively. Subgroup analyses of PFS by stratification factors and MET tumour expression were consistent with results for the overall population. With a median follow-up of 34.5 months, median OS was 26.6 months (95% CI 14.6-not estimable) with cabozantinib and 21.2 months (95% CI 16.3-27.4) with sunitinib (HR 0.80 [95% CI 0.53-1.21]. The incidence of grade 3 or 4 adverse events was 68% for cabozantinib and 65% for sunitinib. CONCLUSIONS: In this phase 2 trial, cabozantinib treatment significantly prolonged PFS per IRC compared with sunitinib as initial systemic therapy for advanced RCC of poor or intermediate risk. TRIAL REGISTRATION NUMBER: NCT01835158.
引用
- Choueiri TK, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018. PMID: 29550566. doi:10.1016/j.ejca.2018.02.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。